CN106455571A - 1,2,4‑噁二唑苯甲酸的药物组合物和盐 - Google Patents
1,2,4‑噁二唑苯甲酸的药物组合物和盐 Download PDFInfo
- Publication number
- CN106455571A CN106455571A CN201580023750.3A CN201580023750A CN106455571A CN 106455571 A CN106455571 A CN 106455571A CN 201580023750 A CN201580023750 A CN 201580023750A CN 106455571 A CN106455571 A CN 106455571A
- Authority
- CN
- China
- Prior art keywords
- salt
- compound
- certain embodiments
- pharmaceutical composition
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110248825.5A CN112979575A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
| CN202110248539.9A CN112979574A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949052P | 2014-03-06 | 2014-03-06 | |
| US61/949,052 | 2014-03-06 | ||
| US201462009111P | 2014-06-06 | 2014-06-06 | |
| US62/009,111 | 2014-06-06 | ||
| PCT/US2015/018889 WO2015134711A1 (en) | 2014-03-06 | 2015-03-05 | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110248539.9A Division CN112979574A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
| CN202110248825.5A Division CN112979575A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106455571A true CN106455571A (zh) | 2017-02-22 |
Family
ID=54055864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580023750.3A Pending CN106455571A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
| CN202110248539.9A Pending CN112979574A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
| CN202110248825.5A Pending CN112979575A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110248539.9A Pending CN112979574A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
| CN202110248825.5A Pending CN112979575A (zh) | 2014-03-06 | 2015-03-05 | 1,2,4-噁二唑苯甲酸的药物组合物和盐 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9873677B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3113619A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6946001B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20230024431A (cg-RX-API-DMAC7.html) |
| CN (3) | CN106455571A (cg-RX-API-DMAC7.html) |
| CA (2) | CA2942147C (cg-RX-API-DMAC7.html) |
| EA (1) | EA032779B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL247653B (cg-RX-API-DMAC7.html) |
| TW (2) | TWI636978B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015134711A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006235115C1 (en) | 2005-04-08 | 2013-02-28 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| UA99600C2 (en) * | 2006-09-25 | 2012-09-10 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| WO2015134711A1 (en) * | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| TW201729807A (zh) | 2015-10-30 | 2017-09-01 | Ptc治療公司 | 用於治療癲癇的方法 |
| EP3377476B1 (en) * | 2015-11-16 | 2022-10-26 | PTC Therapeutics, Inc. | Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof |
| CA3048202A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by inhibition of nonsense mediated decay |
| JP2020525434A (ja) | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法 |
| WO2019101709A1 (en) | 2017-11-23 | 2019-05-31 | Universita' Degli Studi Di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
| CN109678715B (zh) * | 2018-11-28 | 2019-11-12 | 中国药科大学 | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 |
| US10637694B1 (en) | 2018-12-21 | 2020-04-28 | At&T Intellectual Property I, L.P. | Reduction and/or mitigation of spatial emissions in multi-antenna wireless communication systems for advanced networks |
| KR20210151131A (ko) | 2019-04-10 | 2021-12-13 | 피티씨 테라퓨틱스, 인크. | 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법 |
| WO2022128876A1 (en) * | 2020-12-14 | 2022-06-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ataluren eye drop formulation |
| US20250255816A1 (en) * | 2022-04-18 | 2025-08-14 | Vanderbilt University | Polysulfide microparticles and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1802360A (zh) * | 2003-04-11 | 2006-07-12 | Ptc治疗公司 | 1,2,4-噁二唑苯甲酸化合物 |
| CN101193632A (zh) * | 2005-04-08 | 2008-06-04 | Ptc医疗公司 | 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物 |
| CN101553226A (zh) * | 2006-10-12 | 2009-10-07 | Ptc医疗公司 | 给用口服活性1,2,4-噁二唑进行无义突变抑制治疗的方法 |
| WO2011072281A1 (en) * | 2009-12-11 | 2011-06-16 | Ptc Therapeutics, Inc. | Methods for treating methylmalonic acidemia |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL291628A (cg-RX-API-DMAC7.html) | 1962-04-17 | |||
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4016170A (en) | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
| US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| US4166732A (en) | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
| US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
| US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
| TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
| US6071700A (en) | 1995-01-20 | 2000-06-06 | University Of Massachusetts | Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions |
| EP0853626A1 (en) | 1995-09-07 | 1998-07-22 | Novartis AG | Substituted phosphinic compounds and their use as pharmaceuticals |
| WO1997041105A1 (en) | 1996-04-26 | 1997-11-06 | Nippon Soda Co., Ltd. | Novel heterocycle-substituted benzene derivatives and herbicides |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| JP2000511903A (ja) | 1996-06-07 | 2000-09-12 | メルク エンド カンパニー インコーポレーテッド | 糖尿病および肥満の治療のための選択性β▲下3▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド |
| US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
| DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
| ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
| ES2329739T3 (es) | 1997-04-07 | 2009-11-30 | Georgetown University | Analogos de cocaina. |
| US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
| AU9647998A (en) | 1997-10-27 | 1999-05-17 | Nippon Soda Co., Ltd. | Novel benzoylpyrazole derivatives and herbicides |
| IL139187A0 (en) | 1998-04-23 | 2001-11-25 | Cortech Inc | Cysteine protease inhibitors |
| CA2346689A1 (en) | 1998-10-08 | 2000-04-20 | Gregor James Macdonald | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| EP1119568B1 (en) | 1998-10-09 | 2004-02-18 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
| BR9916488A (pt) | 1998-12-23 | 2001-10-09 | Smithkline Beecham Corp | Inibidores de protease |
| WO2000058280A1 (en) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Carbocyclic sulfonamide derivatives |
| AU3196200A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
| WO2000058304A1 (en) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Heterocyclic sulfonamide derivatives |
| AU4537900A (en) | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| US6498151B2 (en) | 2000-03-22 | 2002-12-24 | Merck Frosst Canada & Co. | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| AU2001248765A1 (en) | 2000-04-21 | 2001-11-12 | Shionogi And Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
| GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
| DZ3347A1 (fr) | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| CA2342432A1 (en) | 2001-03-28 | 2002-09-28 | Christopher Norbert Johnson | Novel compound |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| BR0209054A (pt) | 2001-04-19 | 2004-04-20 | Bayer Ag | Arilsulfonamidas como agentes antivirais |
| US7041685B2 (en) | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| EP1405636A4 (en) | 2001-06-26 | 2009-04-15 | Takeda Pharmaceutical | FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| JP2006521344A (ja) | 2003-03-28 | 2006-09-21 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症および肥満の治療のためのcetp阻害剤としての1,2,4−置換1,2,3,4−テトラヒドロ−および1,2−ジヒドロ−キノリンおよび1,2,3,4−テトラヒドロ−キノキサリン誘導体 |
| US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| JP5255183B2 (ja) | 2003-09-04 | 2013-08-07 | ウォックハート リミテッド | ベンゾキノリジン−2−カルボン酸アルギニン塩四水和物 |
| GB0321827D0 (en) | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005097096A1 (en) * | 2004-03-31 | 2005-10-20 | Pharmacia & Upjohn Company Llc | A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders |
| JP2008515992A (ja) | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス,インコーポレーテッド | 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用 |
| AU2006235115C1 (en) * | 2005-04-08 | 2013-02-28 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| EP2387995A1 (en) * | 2006-03-30 | 2011-11-23 | PTC Therapeutics, Inc. | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
| WO2007123848A2 (en) | 2006-04-19 | 2007-11-01 | Brown University | Therapeutic compositions containing modified class i slrp proteins |
| NZ598012A (en) * | 2006-09-08 | 2013-08-30 | Ptc Therapeutics Inc | Processes for the preparation of 1,2,4-oxadiazole benzoic acids |
| US8101641B2 (en) | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
| UA99600C2 (en) | 2006-09-25 | 2012-09-10 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
| CN101970420B (zh) | 2007-10-04 | 2014-09-24 | 默克雪兰诺有限公司 | 噁二唑衍生物 |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2234625B8 (en) | 2007-12-17 | 2013-10-30 | The Regents of the University of Michigan | Compositions and methods for treating and preventing skeletal muscle deficiencies |
| MX2010010300A (es) * | 2008-03-19 | 2010-10-26 | Osi Pharm Inc | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. |
| WO2010008831A2 (en) | 2008-06-24 | 2010-01-21 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
| NZ605452A (en) | 2008-07-14 | 2014-05-30 | Ferrokin Biosciences Inc | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| AU2009302478B2 (en) | 2008-10-07 | 2015-09-03 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| RU2398770C1 (ru) | 2009-03-27 | 2010-09-10 | Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) | Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота |
| EP2559443A1 (en) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| WO2014153643A1 (en) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
| WO2015134711A1 (en) * | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| WO2015188037A1 (en) | 2014-06-06 | 2015-12-10 | Ptc Therapeutics, Inc. | Methods of treatment using a 1,2,4-oxadiazole benzoic acid |
-
2015
- 2015-03-05 WO PCT/US2015/018889 patent/WO2015134711A1/en not_active Ceased
- 2015-03-05 TW TW104107343A patent/TWI636978B/zh not_active IP Right Cessation
- 2015-03-05 TW TW107124154A patent/TWI695717B/zh not_active IP Right Cessation
- 2015-03-05 KR KR1020237003980A patent/KR20230024431A/ko not_active Ceased
- 2015-03-05 CN CN201580023750.3A patent/CN106455571A/zh active Pending
- 2015-03-05 CA CA2942147A patent/CA2942147C/en active Active
- 2015-03-05 US US15/123,309 patent/US9873677B2/en not_active Expired - Fee Related
- 2015-03-05 CA CA3174516A patent/CA3174516A1/en active Pending
- 2015-03-05 JP JP2016555713A patent/JP6946001B2/ja not_active Expired - Fee Related
- 2015-03-05 KR KR1020167027606A patent/KR102497273B1/ko active Active
- 2015-03-05 CN CN202110248539.9A patent/CN112979574A/zh active Pending
- 2015-03-05 EA EA201691789A patent/EA032779B1/ru not_active IP Right Cessation
- 2015-03-05 CN CN202110248825.5A patent/CN112979575A/zh active Pending
- 2015-03-05 EP EP15757755.2A patent/EP3113619A4/en not_active Withdrawn
-
2016
- 2016-09-05 IL IL247653A patent/IL247653B/en unknown
-
2017
- 2017-12-12 US US15/838,478 patent/US10233161B2/en active Active
-
2019
- 2019-01-18 US US16/251,318 patent/US10618877B2/en active Active
- 2019-11-22 JP JP2019211430A patent/JP7335795B2/ja active Active
-
2021
- 2021-07-05 JP JP2021111631A patent/JP2021165299A/ja not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1802360A (zh) * | 2003-04-11 | 2006-07-12 | Ptc治疗公司 | 1,2,4-噁二唑苯甲酸化合物 |
| US7419991B2 (en) * | 2003-04-11 | 2008-09-02 | Ptc Therapeutics, Inc. | 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, compositions, and methods for the use thereof |
| US20120277234A1 (en) * | 2003-04-11 | 2012-11-01 | Gary Mitchell Karp | 1,2,4-oxadiazole benzoic acids |
| US8486982B2 (en) * | 2003-04-11 | 2013-07-16 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acids |
| CN101193632A (zh) * | 2005-04-08 | 2008-06-04 | Ptc医疗公司 | 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物 |
| CN101553226A (zh) * | 2006-10-12 | 2009-10-07 | Ptc医疗公司 | 给用口服活性1,2,4-噁二唑进行无义突变抑制治疗的方法 |
| WO2011072281A1 (en) * | 2009-12-11 | 2011-06-16 | Ptc Therapeutics, Inc. | Methods for treating methylmalonic acidemia |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021165299A (ja) | 2021-10-14 |
| US20170066730A1 (en) | 2017-03-09 |
| TW201620883A (zh) | 2016-06-16 |
| US9873677B2 (en) | 2018-01-23 |
| IL247653B (en) | 2022-04-01 |
| KR20230024431A (ko) | 2023-02-20 |
| JP2017507158A (ja) | 2017-03-16 |
| CA3174516A1 (en) | 2015-09-11 |
| TWI636978B (zh) | 2018-10-01 |
| JP2020045354A (ja) | 2020-03-26 |
| TWI695717B (zh) | 2020-06-11 |
| EP3113619A1 (en) | 2017-01-11 |
| CN112979575A (zh) | 2021-06-18 |
| IL247653A0 (en) | 2016-11-30 |
| EP3113619A4 (en) | 2017-09-13 |
| KR102497273B1 (ko) | 2023-02-07 |
| JP7335795B2 (ja) | 2023-08-30 |
| JP6946001B2 (ja) | 2021-10-06 |
| CA2942147A1 (en) | 2015-09-11 |
| US20180179170A1 (en) | 2018-06-28 |
| US10233161B2 (en) | 2019-03-19 |
| US10618877B2 (en) | 2020-04-14 |
| US20190152931A1 (en) | 2019-05-23 |
| EA201691789A1 (ru) | 2017-02-28 |
| KR20160122268A (ko) | 2016-10-21 |
| WO2015134711A1 (en) | 2015-09-11 |
| CN112979574A (zh) | 2021-06-18 |
| CA2942147C (en) | 2022-12-13 |
| TW201836605A (zh) | 2018-10-16 |
| EA032779B1 (ru) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7335795B2 (ja) | 薬学的組成物、および1,2,4-オキサジアゾール安息香酸の塩 | |
| JP7860054B2 (ja) | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 | |
| US10172852B2 (en) | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug | |
| US20100311688A1 (en) | Ophthalmic formulations, methods of manufacture, and methods of using same | |
| TW200911265A (en) | Pharmaceutical compositions and methods of treating dry eye disorders | |
| JP7365056B6 (ja) | 眼充血を治療するための組成物およびそれを用いて眼充血を治療するための方法 | |
| JP2026004320A (ja) | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤 | |
| JP2026004313A (ja) | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤 | |
| JP2010533221A (ja) | プロスタグランジン誘導体と1置換荷電ベータシクロデキストリンとの複合体 | |
| HK40058574A (en) | Pharmaceutical compositions and salts of a 1,2,4- oxadiazole benzoic acid | |
| HK40054075A (en) | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid | |
| TWI816660B (zh) | 噻托銨用於製造預防近視、治療近視及/或預防近視增長之點眼劑之用途 | |
| HK1230865A1 (en) | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid | |
| RU2853589C2 (ru) | Составы на основе 4-(7-гидрокси-2-изопропил-4-оксо-4h-хиназолин-3-ил)-бензонитрила | |
| CN120752043A (zh) | 治疗白内障手术并发症之方法 | |
| CN120187411A (zh) | 用于缓解眼部发红的包含阿可乐定的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1230865 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1230865 Country of ref document: HK |